Stockholders Approve Incentive Plan Authorizing 14.75% Potential Dilution
RARE sits 33% above its 52-week low of $18.29 on light trading volume (0.2× avg).
Summary
Ultragenyx Pharmaceutical Inc. stockholders approved an amended incentive plan, authorizing the issuance of up to 14.5 million new shares, which could lead to a potential dilution of approximately 14.75% of outstanding shares.
Key Events · Financing and Capital Events · RARE
-
Incentive Plan Approved
Stockholders approved the Third Amended and Restated 2023 Incentive Plan at the Annual Meeting on May 14, 2026.
-
Significant Share Authorization
The approved plan authorizes the issuance of up to 14,500,000 new shares for equity awards.
-
Potential Dilution
If all authorized shares were issued, dilution would be approximately 14.75% based on the 98,317,221 shares outstanding as of March 23, 2026.
-
Routine Annual Meeting Outcomes
Other proposals, including the election of three Class I directors, ratification of Ernst & Young LLP as the independent accounting firm, and an advisory vote on executive compensation, were also approved.
Analysis · RARE · Life Sciences
The approval of the Third Amended and Restated 2023 Incentive Plan by stockholders authorizes Ultragenyx to issue up to 14.5 million new shares for equity awards. This represents a substantial potential dilution of approximately 14.75% of the company's currently outstanding shares. While incentive plans are standard for attracting and retaining talent, the magnitude of this authorization creates a significant overhang for existing shareholders, as these shares will be issued over time, increasing the total share count.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $24.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.29 to $42.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.